

## CELLINK announces further right-sizing and launches sharpened commercial agenda

**CELLINK Bioprinting AB (“CELLINK”), an operating company within the BICO Group AB (“BICO”), has today launched a plan for long-term stability and profitability. This entails a sharpened commercial agenda and further right-sizing to achieve a sustainable cost structure.**

Measures taken will result in a solid platform to scale from and lay the foundation for sustainable profitable growth. It will also entail an increased focus on the technologies where CELLINK has a leading market position and to optimize synergies with other BICO companies, which is in line with the Group’s updated strategy which was launched during the Capital Market’s Day in Mid-September 2024.

*“This is aligned with the Group’s updated commercial strategy and our financial targets. This will sharpen CELLINK’s commercial offering and support our transformation and ensure long-term sustainable profitable growth”,* says Maria Forss, President and CEO, BICO Group AB.

The rightsizing is expected to result in redundancy of approximately 20 percent of the employees across the CELLINK organization. Redundancies are subject to union negotiations.

*“These measures will enable us to further develop the business on its scientific and commercial strengths. CELLINK will move forward as a tighter and a more cost-effective organization with a continued focus on our key priorities”,* says Stefan Blomsterberg, CEO CELLINK Bioprinting AB.

### **For further information, please contact:**

Maria Forss, President & CEO, BICO Group AB

Phone: EA Isabella Lundin +46 73 515 99 64

E-mail: [mf@bico.com](mailto:mf@bico.com)

*The information was submitted for publication, through the agency of the contact person set out above, on November 25, 2024 at 7pm CET.*

### **About BICO**

**BICO** is a lab automation partner and provider of selected workflows to pharma and biotech. With 46,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 12,000 publications. Operating through three business areas – Lab Automation, Life Science Solutions, and Bioprinting – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. [www.bico.com](http://www.bico.com)

### **About CELLINK**

**CELLINK** partners with researchers across segments to deliver 3D cell culture solutions that drive scientific breakthroughs in drug discovery and translational medicine. By engaging in cutting-edge advancements in bioprinting, CELLINK is at the forefront of the shift towards 3D models.

**PRESS RELEASE**  
25 November 2024 19:00:00 CET



**Attachments**

[CELLINK announces further right-sizing and launches sharpened commercial agenda](#)